Biologics, Biosimilars, and Biobetters: Therapeutic Innovations Reshaping Modern Medicine
Source abstract
Abstract
Abstract Biologic medicines (or biologics) have revolutionized the treatment of cancer, autoimmune disorders, and genetic conditions. Their therapeutic success stems from complex structural properties that confer high target specificity and biological compatibility. However, their high cost and complex manufacturing limit patient access, with annual treatment expenses often reaching tens of thousands of dollars per patient. Biosimilars, developed to match reference biologics in quality, safety, and efficacy, provide a pathway to curb escalating costs. Having generated more than 36 billion USD in healthcare savings over the past decade, their wider adoption remains challenged by stringent regulatory pathways and the market exclusivity of reference products. These limitations have spurred the development of biobetters, which are engineered biologics with enhanced stability, potency, half‐life, or reduced immunogenicity that maximize patient benefit. This review explores the distinctions, development strategies, and regulatory challenges of biologics, biosimilars, and biobetters. Biosimilarity establishment and biobetter design strategies are examined with emphasis on enzyme‐based examples such as L‐asparaginase and glucarpidase. Advanced delivery technologies have also been demonstrated to improve drug stability, bioavailability, and patient adherence. Finally, emerging innovations and future directions underscore the transformative potential of these biopharmaceuticals in addressing unmet medical needs and expanding global access.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Biosimilars and Bioanalytical Methods · Transgenic Plants and Applications · Monoclonal and Polyclonal Antibodies Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biochemistry Faculty of Science Mahidol University Bangkok 10400 Thailand
Genetics and Molecular Biology Division Institute of Biological Sciences College of Arts and Sciences University of the Philippines Los Baños College Laguna 4031 Philippines
References (100+)
Show source-provided references
1. 10.1111/j.1365-2133.2006.07225.x10.1111/j.1365-2133.2006.07225.x ↗
2. Walsh G. · Eur. J. Pharm. Biopharm. · 2002 · 15 · 135
3. 10.9734/BBJ/2016/2574210.9734/BBJ/2016/25742 ↗
4. 10.56808/3027-7922.216510.56808/3027-7922.2165 ↗
5. 10.1016/j.copbio.2019.11.00410.1016/j.copbio.2019.11.004 ↗
6. 10.1038/s41587-022-01582-x10.1038/s41587-022-01582-x ↗
7. 10.1002/bab.161710.1002/bab.1617 ↗
8. John S. · Int. J. Chem. Biochem. Sci. · 2023 · 24 · 478
9. 10.1038/nbt.193610.1038/nbt.1936 ↗
10. 10.1111/cbdd.1205510.1111/cbdd.12055 ↗
11. 10.21103/Article12(1)_GE10.21103/Article12(1)_GE ↗
12. Bhojaraj S. · Pharmacol. Neurol. Dis. · 2021 · 11 · 7
13. 10.4161/mabs.3.2.1500510.4161/mabs.3.2.15005 ↗
14. 10.1038/nbt0708-74310.1038/nbt0708-743 ↗
15. Liew K. B. · Biomed. Biopharm. Res. · 2023 · 20 · 118
16. Steinberg F. M. · J. Pharm. Pharm. Sci. · 1998 · 1 · 48
17. 10.1056/NEJMra04318610.1056/NEJMra043186 ↗
18. 10.1634/theoncologist.2009-031710.1634/theoncologist.2009-0317 ↗
19. 10.1016/j.ejpb.2004.03.01210.1016/j.ejpb.2004.03.012 ↗
20. Noble A. · Immunology · 1995 · 85 · 357
21. 10.1056/NEJM19971009337150210.1056/NEJM199710093371502 ↗
22. 10.1016/S0168-8278(03)00152-110.1016/S0168-8278(03)00152-1 ↗
23. 10.1016/S0958-1669(03)00092-210.1016/S0958-1669(03)00092-2 ↗
24. 10.1634/theoncologist.12-8-99110.1634/theoncologist.12-8-991 ↗
25. 10.2165/00063030-200317010-0000310.2165/00063030-200317010-00003 ↗
26. 10.3390/ph1610141610.3390/ph16101416 ↗
27. 10.1186/s12967-024-05179-710.1186/s12967-024-05179-7 ↗
28. 10.52965/001c.2493410.52965/001c.24934 ↗
29. 10.1016/j.semarthrit.2016.01.00110.1016/j.semarthrit.2016.01.001 ↗
30. 10.1038/s41433-019-0391-510.1038/s41433-019-0391-5 ↗
31. 10.1002/btpr.206610.1002/btpr.2066 ↗
32. Food U. S. · 2018
33. 10.1200/JOP.2017.02606210.1200/JOP.2017.026062 ↗
34. 10.2217/fon-2023-075610.2217/fon-2023-0756 ↗
35. 10.1016/j.biologicals.2013.11.00910.1016/j.biologicals.2013.11.009 ↗
36. 10.1080/03007995.2017.128861210.1080/03007995.2017.1288612 ↗
37. 10.1136/annrheumdis-2012-20271510.1136/annrheumdis-2012-202715 ↗
38. 10.5639/gabij.2014.0304.03910.5639/gabij.2014.0304.039 ↗
39. Biosimilars Council and Association for Accessible Medicines. 2024 U.S. Generic & Biosimilar Medicines Savings Report. 2024 https://biosimilarscouncil.org/resource/2024‐us‐generic‐biosimilar‐savings‐report/.
40. Chen H.‐H. · PLoS One · 2012 · 19
41. 10.3390/ph504035310.3390/ph5040353 ↗
42. Bonilla J. W. · BioProcess Int. · 2011 · 9 · 22
43. European Medicines Agency · 2019
44. 10.1038/nrd230710.1038/nrd2307 ↗
45. 10.1111/bcp.1265610.1111/bcp.12656 ↗
46. 10.1007/s40259-015-0133-610.1007/s40259-015-0133-6 ↗
47. 10.1016/j.csbj.2017.01.00310.1016/j.csbj.2017.01.003 ↗
48. 10.1038/nbt.160110.1038/nbt.1601 ↗
49. 10.5530/ijpi.13.4.08810.5530/ijpi.13.4.088 ↗
50. Mullard A. · Nat. Rev. Drug Discov. · 2016 · 15 · 447
51. 10.1007/s40259-024-00662-510.1007/s40259-024-00662-5 ↗
52. 10.1177/2040622323122328610.1177/20406223231223286 ↗
53. 10.1007/s40259-024-00671-410.1007/s40259-024-00671-4 ↗
54. 10.1007/s40268-024-00471-910.1007/s40268-024-00471-9 ↗
55. 10.1007/s40268-024-00485-310.1007/s40268-024-00485-3 ↗
56. 10.1016/j.jchromb.2023.12389610.1016/j.jchromb.2023.123896 ↗
57. 10.1007/s40259-020-00404-310.1007/s40259-020-00404-3 ↗
58. 10.1007/s40259-023-00591-910.1007/s40259-023-00591-9 ↗
59. 10.1016/j.drudis.2019.03.01610.1016/j.drudis.2019.03.016 ↗
60. Sassi A. B. · 2015
61. Alten R. · Clin Microbiol. Infect. · 2022 · 42 · 477
62. 10.1093/crocol/otad04010.1093/crocol/otad040 ↗
63. 10.1038/s41598-024-75693-710.1038/s41598-024-75693-7 ↗
64. 10.1016/j.bpg.2025.10199210.1016/j.bpg.2025.101992 ↗
65. 10.1093/ecco-jcc/jjy02010.1093/ecco-jcc/jjy020 ↗
66. 10.1093/jcag/gwad03210.1093/jcag/gwad032 ↗
67. 10.1016/j.autrev.2021.10284910.1016/j.autrev.2021.102849 ↗
68. 10.3389/fchem.2020.0062210.3389/fchem.2020.00622 ↗
69. 10.1016/j.jbiotec.2019.07.00610.1016/j.jbiotec.2019.07.006 ↗
70. 10.1039/c2cs15289d10.1039/c2cs15289d ↗
71. 10.1016/j.addr.2007.04.01710.1016/j.addr.2007.04.017 ↗
72. 10.1002/biot.20090021810.1002/biot.200900218 ↗
73. 10.1016/S0968-0004(01)01906-510.1016/S0968-0004(01)01906-5 ↗
74. 10.1038/onc.2016.3710.1038/onc.2016.37 ↗
75. 10.2174/15665241079131699510.2174/156652410791316995 ↗
76. 10.1111/j.1349-7006.1993.tb02821.x10.1111/j.1349-7006.1993.tb02821.x ↗
77. 10.1016/j.canlet.2014.11.04210.1016/j.canlet.2014.11.042 ↗
78. 10.1016/j.drudis.2021.08.00910.1016/j.drudis.2021.08.009 ↗
79. 10.1039/C8SC01777H10.1039/C8SC01777H ↗
80. 10.3109/07388551.2013.83429310.3109/07388551.2013.834293 ↗
81. 10.1021/bc500215m10.1021/bc500215m ↗
82. 10.1038/nbt.158810.1038/nbt.1588 ↗
83. 10.1634/theoncologist.2020-010510.1634/theoncologist.2020-0105 ↗
84. 10.1038/s41598-021-04560-610.1038/s41598-021-04560-6 ↗
85. 10.1007/s12010-023-04522-w10.1007/s12010-023-04522-w ↗
86. 10.1093/protein/gzt02310.1093/protein/gzt023 ↗
87. 10.1021/acsomega.2c0407110.1021/acsomega.2c04071 ↗
88. 10.1007/s11274-019-2731-910.1007/s11274-019-2731-9 ↗
89. 10.1016/j.cmet.2018.04.01210.1016/j.cmet.2018.04.012 ↗
90. 10.1038/nature2546510.1038/nature25465 ↗
91. 10.1186/s12943-017-0623-x10.1186/s12943-017-0623-x ↗
92. 10.1016/j.cmet.2017.12.00610.1016/j.cmet.2017.12.006 ↗
93. 10.1016/j.cmet.2020.03.00810.1016/j.cmet.2020.03.008 ↗
94. 10.18632/oncotarget.286910.18632/oncotarget.2869 ↗
95. 10.1038/s41388-022-02474-910.1038/s41388-022-02474-9 ↗
96. 10.1038/s41420-024-02142-910.1038/s41420-024-02142-9 ↗
97. 10.1200/JCO.1993.11.9.178010.1200/JCO.1993.11.9.1780 ↗
98. 10.1016/j.bbagen.2023.13049910.1016/j.bbagen.2023.130499 ↗
99. 10.1002/cncr.2548910.1002/cncr.25489 ↗
100. 10.1002/pbc.2222510.1002/pbc.22225 ↗